Why is it introduced/or Produced in the sample?

Why do we need to test for the analyte?

What is the regulatory requirement of Pharmaceutical Excipient Testing in India?

What is the global/importing country requirement?

USA

Under U.S. law, excipients do not possess the same regulatory status as active drug substances. As such, they cannot be marketed for use in food or approved medications unless they fulfill specific qualifications set forth by the U.S. Food and Drug Administration (FDA). The approval mechanisms include:

● Determination by the FDA that the substance is “generally recognized as safe” (GRAS), as specified in Title 21 of the U.S. Code of Federal Regulations (CFR), Parts 182, 184, or 186.

● Approval of a food additive petition outlined in 21 CFR 171. 

● Documenting the excipient in an NDA for intended drug product application. 

Additionally, for excipients used in over-the-counter (OTC) drug products governed by FDA monographs in 21 CFR Parts 331-358, compliance with the requirements set forth in 21 CFR 330.1(e) is essential. This regulatory framework ensures that excipients meet strict safety and quality standards, protecting public health while enabling the pharmaceutical industry to innovate effectively. 

Europe: 

The manufacture and utilization of excipients are closely monitored by the European Medicines Agency (EMA), ensuring compliance with the 2011/62/EU Falsified Medicines Directive. Key requirements of pharmaceutical excipient testing involve rigorous standards and procedures to guarantee the safety and efficacy of medicinal products.

● Manufacturers are obligated to ensure that excipients comply with Good Manufacturing Practices (GMP).

● A formal risk assessment process must be conducted to confirm compliance with GMP, as specified in Eudralex Vol 4 Part 1, Chapter 5.

●Thorough documentation of the selection, qualification, approval, and ongoing monitoring of suppliers must be maintained.

● The level of oversight for suppliers should be proportionate to the associated risks, with documentation supporting supplier approvals retained.

The EMA’s framework emphasizes the importance of ensuring that excipients used in medicinal products adhere to rigorous safety and quality standards. By enforcing these regulations, the EMA strives to protect public health while fostering accountability within the pharmaceutical supply chain.

European market & regulation EC2015/C95/02

The European Union has set in motion a formal risk assessment process to identify the appropriate Good Manufacturing Practices (GMP) for excipients used in medicinal products destined for human application. Manufacturers possessing authorization must ensure that their documentation on risk assessment and GMP management concerning excipient testing is readily available for scrutiny by GMP auditors. Additionally, exchanging relevant details from the risk assessment with the excipient manufacturer is advisable to drive continuous improvement efforts.

Excipients described in the European Pharmacopoeia

When a monograph encompasses a group of related substances, the specific specification selected for the excipient must be submitted along with the rationale supporting its choice.  Any alternative methods not listed in the pharmacopoeia require convincing evidence to prove they are at least as effective as outlined procedures. In cases where an excipient is absent from the European Pharmacopoeia, compliance with a recognized monograph from another country’s pharmacopoeia (such as USP or JP) is permissible. For excipients not found in any pharmacopoeia, it is vital to establish an appropriate specification that includes: physical characteristics, identification tests, purity tests (with limits for both total and individual impurities, encompassing physical, chemical, biological, and immunological aspects if necessary), and assay or limit tests.

Harmonisation of Excipient monographs (PDG)

The Pharmacopoeial Discussion Group (PDG) includes the European (Ph. Eur.), Japanese (JP), and United States Pharmacopeia (USP) and aims to resolve discrepancies among them under the International Conference on Harmonization (ICH). It focuses on harmonizing pharmacopoeial monographs through a common understanding of their purpose and structure.

Key components of excipient monographs are identification, characterization, impurity control, and assay, with analytical techniques chosen based on availability and control level. Developing standardized compendial standards is a significant achievement, reflecting the PDG partners’ commitment to consistent global standards in excipient manufacturing and use.

How will it help the business?

Routine pharmaceutical excipient testing of excipients prior to formulation is vital for guaranteeing the safety and efficacy of the final drug product. This process represents not only sound business practice but also a key regulatory requirement. Global regulatory authorities enforce testing to verify the identity of excipients and confirm that they comply with established specifications concerning purity, strength, and quality. Such diligence supports the overall integrity of pharmaceutical products, fosters consumer trust, and aligns with industry standards.

How will it help the consumer/customer? 

Regulatory authorities are emphasizing the importance of establishing robust supply chains and precise quality standards for pharmaceutical excipient testing, increasingly adopting risk management strategies to strengthen patient safety. This revitalized focus promises reliable and effective medications for all users. 

Why do you need to choose Auriga Research for your excipient testing requirements?

Auriga Research Laboratories routinely conducts comprehensive monograph testing for excipients. Equipped with state-of-the-art instruments and a team of experienced professionals, we adhere to international testing standards. Our extensive presence across pan-India locations ensures we are readily available to meet your business needs. We offer tailored testing services and ensure regulatory compliance, thereby facilitating your path to an uninterrupted and successful operation.

If you have questions or queries about pharmaceutical excipient testing or need expert consultation, kindly fill out our query form. We would be pleased to craft a tailored proposal that suits your testing needs.